Free. Unsubscribe any time.
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. filed 28 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 6 reporting owners, covering 28 transactions and 33,595 shares. 28 carry the SEC's AFF10B5ONE flag; 0 name a plan only in a footnote. 8 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-08-18, came on the same day as the one before it (2026-08-18) and reports 4 transactions against 4 in the filing before it.
- The sales it reports total 64 shares, 199 fewer than the 263 in the filing before it.
- Its 28 plan statements rank 214th of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 3 have more plan statements on file than it and 7 have fewer.
- Its 28 filings on file run from 2025-02-19 to 2026-08-18, and state 5 plan adoption dates, from 2023-03-02 to 2025-11-26.
Trades in Seres Therapeutics, Inc. 28
- DesRosier Thomas — 2025-02-18 · S · 4,300 shares
- Henn Matthew R. — 2025-02-18 · S · 3,953 shares
- Shaff Eric D. — 2025-02-18 · S · 12,726 shares
- Young Teresa L. — 2025-02-18 · S · 3,338 shares
- von Moltke Lisa — 2025-02-18 · S · 4,416 shares
- DesRosier Thomas — 2025-05-15 · S · 79 shares
- Henn Matthew R — 2025-05-16 · S · 77 shares
- Shaff Eric D. — 2025-05-16 · S · 220 shares
- Young Teresa L. — 2025-05-16 · S · 63 shares
- DesRosier Thomas — 2025-08-18 · S · 76 shares
- Henn Matthew R — 2025-08-18 · S · 73 shares
- Shaff Eric D. — 2025-08-18 · S · 217 shares
Adoption dates in Seres Therapeutics, Inc. 5
- 2023-03-02 — stated in 14 filings
- 2023-03-05 — stated in 5 filings
- 2023-03-11 — stated in 1 filing
- 2023-04-13 — stated in 7 filings
- 2025-11-26 — stated in 1 filing
Results prints in Seres Therapeutics, Inc. 8
- 2025-01-10
- 2025-03-13
- 2025-05-07
- 2025-08-06
- 2025-11-05
- 2026-03-12
- 2026-05-05
- 2026-08-05
Trades before a print in Seres Therapeutics, Inc. 0
- 23 days before the 2025-03-13 print — 2025-02-18 · S · DesRosier Thomas · 4,300 shares
- 23 days before the 2025-03-13 print — 2025-02-18 · S · Henn Matthew R. · 3,953 shares
- 23 days before the 2025-03-13 print — 2025-02-18 · S · Shaff Eric D. · 12,726 shares
- 23 days before the 2025-03-13 print — 2025-02-18 · S · Young Teresa L. · 3,338 shares
- 23 days before the 2025-03-13 print — 2025-02-18 · S · von Moltke Lisa · 4,416 shares
- 25 days before the 2026-03-12 print — 2026-02-15 · S · DesRosier Thomas · 78 shares
- 25 days before the 2026-03-12 print — 2026-02-15 · S · Henn Matthew R · 89 shares
- 25 days before the 2026-03-12 print — 2026-02-15 · S · Shaff Eric D. · 259 shares
- 25 days before the 2026-03-12 print — 2026-02-15 · S · Young Teresa L. · 75 shares
- 79 days before the 2025-11-05 print — 2025-08-18 · S · DesRosier Thomas · 76 shares
- 79 days before the 2025-11-05 print — 2025-08-18 · S · Henn Matthew R · 73 shares
- 79 days before the 2025-11-05 print — 2025-08-18 · S · Shaff Eric D. · 217 shares
Interval to Seres Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 0within 5 days
- 0within 10 days
- 23shortest, days
- 4no later print
Adoption dates Seres Therapeutics, Inc. states
- 2023-03-02 in 14 filings
- 2023-03-05 in 5 filings
- 2023-03-11 in 1 filing
- 2023-04-13 in 7 filings
- 2025-11-26 in 1 filing
Filing text: “10b5-1 instruction adopted by the reporting person on March 11, 2023”
Reported results dates on file
- 2025-01-10
- 2025-03-13
- 2025-05-07
- 2025-08-06
- 2025-11-05
- 2026-03-12
- 2026-05-05
- 2026-08-05
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.